131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status
about
Cancer immunotherapy based on the killing of Salmonella typhimurium-infected tumour cells.PPARgamma in Neuroblastoma.The role of 131I-MIBG in high-risk neuroblastoma treatment.Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors.An epidural neuroblastoma causing spinal cord compression in a 67-year-old woman.Meeting the nursing challenges in treating children with 131I-MIBG.
P2860
131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status
@en
131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status.
@ast
type
label
131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status
@en
131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status.
@ast
prefLabel
131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status
@en
131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status.
@ast
P2860
P1476
131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status
@en
P2093
S Tepmongkol
P2860
P304
427-31; discussion 432
P356
10.1002/(SICI)1096-911X(199906)32:6<427::AID-MPO6>3.0.CO;2-T
P407
P577
1999-06-01T00:00:00Z